Since joining the SEEK group I have worked as Head of Biology across the SEEK group. I have brought his expertise and knowledge to drive on the Group’s pharmaceutical assets from conception through to completion. I have worked on all facets of product development, including formulation development, clinical program development, regulatory dossier submission and marketing support. Two of these products (Unicough and Flarin) have reached the marketplace. I joined Seek in 2009 after a 12-year career within the biotechnology and pharmaceutical industries. I initially joined a company (PolyMaSC) focusing on technologies enhancing the efficacy of biological medical products involving proteins, liposomes and viruses, such as the adenovirus used in gene therapy. I successfully led a range of projects (e.g. the preclinical development of universal red blood cells and long acting insulin), and was a member of the team that developed a number enhanced pharmaceutical properties of products in late stage development (e.g. factor VIII and Onxy-015). I then joined Arakis and led a number of small molecule anti-inflammatory and analgesic projects, including a treatment for diabetic nephropathy, which I led from inception to Phase II clinical development, a transdermal neuropathic pain programme (which reached non-clinical development), and a small molecule treatment of autoimmune disease, focusing on inflammatory bowel disease (which reached phase I clinical development). I subsequently worked as a consultant for Serentis, a dermal anti-inflammatory company, enhancing their pipeline of dermatitis products.I am an experienced pharmacologist and biologist with an excellent knowledge of a wide range of therapeutic areas, including pain, autoimmune disease, cancer, CNS disorders and metabolic disease.